Gordon E M, Ratnoff O D, Saito H, Donaldson V H, Pensky J, Jones P K
J Lab Clin Med. 1980 Nov;96(5):762-9.
The use of OCAs has been associated with multiple hemostatic abnormalities and an increased risk of thromboembolic disease. These changes have been attributed to increased synthesis of various clotting factors and decreased titers of antithrombin III. Paradoxically, enhanced in vitro fibrinolytic activity is also found in plasmas of women using OCAs. The present study demonstrates marked elevation of both procoagulant and antigenic HF titers in plasmas of women using OCAs, accompanied by a simultaneous decrease in plasma C-1-INH concentration. Titers of plasma prekallikrein, HMW kininogen, PTA, and alpha 2-Pl were unchanged. The rate of kaolin-assisted fibrinolysis was related directly to the titer of HF and inversely to C-1-INH concentration. Further, the addition of human HF to normal plasma enhanced fibrinolytic activity to a degree similar to that observed in plasmas of women taking OCAs. These data suggest that the increase in plasma HF concentration may participate in the phenomenon of enhanced in vitro fibrinolysis associated with OCA use, possibly augmented by diminished inhibitory control by C-1-INH. The relationship of these phenomena to the increased incidence of thrombosis is not known.
口服避孕药(OCAs)的使用与多种止血异常及血栓栓塞性疾病风险增加相关。这些变化归因于各种凝血因子合成增加及抗凝血酶III水平降低。矛盾的是,使用OCAs的女性血浆中也发现体外纤溶活性增强。本研究表明,使用OCAs的女性血浆中促凝血因子和抗原性高分子量激肽原(HF)滴度显著升高,同时血浆C-1酯酶抑制物(C-1-INH)浓度降低。血浆前激肽释放酶、高分子量激肽原、血浆凝血活酶前质(PTA)和α2-纤溶酶抑制物(α2-Pl)的滴度未改变。高岭土辅助纤溶速率与HF滴度直接相关,与C-1-INH浓度呈负相关。此外,向正常血浆中添加人HF可使纤溶活性增强,其程度与服用OCAs的女性血浆中观察到的相似。这些数据表明,血浆HF浓度升高可能参与了与使用OCAs相关的体外纤溶增强现象,可能因C-1-INH抑制作用减弱而加剧。这些现象与血栓形成发生率增加之间的关系尚不清楚。